Regulation of Hematopoietic Stem Cell Self Renewal

描述（由申请人提供）：组织多样性是通过干细胞不对称自我更新分裂产生的。因此，干细胞在分裂过程中的命运决定是组织稳态的基础。像其他类型的成体干细胞一样，造血干细胞（HSC）可以产生具有不同命运的子细胞。由于不受控制的HSC扩增和丢失对机体来说都是致命的，因此必须严格控制自我更新还是分化的决定。因此，了解HSC命运决定的分子机制具有重要的临床意义。本应用的重点是了解p190-B RhoGAP （Rho GTPase活性的负调节因子）在HSC自我更新和命运决定中的作用。我们对p190-B缺失的HSC的分析表明，p190-B对移植后HSC自我更新的调节至关重要。我们发现p190-B的缺失导致连续移植过程中长期植入增强。与原代受体相比，继代受体骨髓中WT hsc的数量减少，而p190-B-null hsc的数量在继代和原代受体之间保持不变。同时，p190- b缺失的造血干细胞保留多潜能谱系分化。因此，在连续移植过程中，p190-B的缺失会阻止HSC耗尽以维持造血功能。在机制水平上，p190-B缺乏不会改变体内和体外HSC细胞周期动力学或存活，因此，表明p190-B在细胞分裂时调节HSC自我更新活性。这些数据表明p190-B在分裂过程中通过调节造血干细胞的命运决定是造血干细胞自我更新的关键调节因子。我们建议确定p190-B在HSC自我更新中调节的信号通路；并确定p190-B及相关信号通路调控HSC命运决定的机制。我们计划使用HSC功能分析，视频显微复制，免疫荧光成像来检查（Aim 1） IGF-1信号和p16Ink4a在p190- b介导的HSC自我更新中的作用；（Aim 2）确定在ai1中鉴定的p190-B和下游信号通路在影响细胞命运决定因子分离以控制不对称/对称自我更新分裂平衡的细胞极性机制中的作用。我们相信对p190-B-null HSC的分析提供了一个难得的机会来鉴定对HSC命运决定重要的干细胞特异性基因。如果我们关于p190-B通过IGF-1/p16Ink4a调控HSC命运决定的假设得到验证，这将显著改变IGF-1信号传导和p16Ink4a在HSC自我更新中的作用的观点。造血干细胞重建造血系统的巨大潜力使得临床造血干细胞移植的发展可以治疗多种疾病。所提出的研究有望为设计临床HSC移植方案的新治疗方法提供依据。

DESCRIPTION (provided by applicant): Tissue diversity is created through stem cell asymmetric self renewal division. Stem cell fate decision during division is thus fundamental for tissue homeostasis. Like other types of adult stem cells, hematopoietic stem cells (HSC) can produce daughter cells with distinct fates. Since both uncontrolled HSC expansion as well as loss of HSC is fatal for the organism, the decision of self renewal versus differentiation must be tightly controlled. An understanding of the molecular mechanism(s) of HSC fate decision is thus of considerable clinical importance. This application focuses on understanding the role of p190-B RhoGAP, a negative regulator of Rho GTPase activity, in HSC self renewal and fate decision. Our analysis of p190-B-null HSC shows that p190-B is essential for the regulation of HSC self renewal following transplantation. We show that loss of p190-B results in enhanced long term engraftment during serial transplantation. While the number of WT HSCs in the bone marrow of secondary recipients decreases in comparison with primary recipients, the numbers of p190-B-null HSCs is maintained between the secondary and primary recipients. At the same time, p190-B-null HSCs retain multipotential lineage differentiation. Thus, loss of p190-B prevents HSC exhaustion to maintain hematopoiesis during serial transplantation. At a mechanistic level, p190-B-deficiency did not alter HSC cell cycle kinetics or survival both in vivo and in vitro - thus, suggesting that p190-B modulates HSC self renewal activity as the cells divide. These data suggest the hypothesis that p190-B is a critical regulator of HSC self renewal by modulating HSC fate decision during divisions. We propose to identify the signaling pathway modulated by p190-B in HSC self renewal; and to determine the mechanism(s) by which p190-B and the associated signaling pathway regulates HSC fate decision. We plan to use functional assays of HSC functions, video microcopy, immunofluorescence imaging to examine (Aim 1) the role of IGF-1 signaling and p16Ink4a in p190-B-mediated HSC self renewal; (Aim 2) determine the role of p190-B and downstream signaling pathway identified in aim1 in mechanism of cell polarity that influences the segregation of cell fate determinant to control the balance of asymmetric/symmetric self renewal divisions. We believe that analysis of p190-B-null HSC offers a rare opportunity to identify stem cell-specific genes that are important for HSC fate decision. If our hypothesis that p190-B regulates HSC fate decision via IGF-1/p16Ink4a is validated, this will significantly change the view of IGF-1 signaling and p16Ink4a functions in HSC self renewal. The tremendous potential of HSC to reconstitute the hematopoietic system has allowed the development of clinical HSC transplantation to treat a wide variety of diseases. The proposed studies are expected to provide rationales to devise new therapeutic approaches of clinical HSC transplantation protocols. PUBLIC HEALTH RELEVANCE: Hematopoietic stem cell self renewal is a fundamental process to maintain continuous blood cell production throughout life. Deregulation of HSC self renewal leads to cancer or tissue degeneration. The tremendous potential of HSC to reconstitute the hematopoietic system has allowed the development of clinical HSC transplantation to treat a wide variety of diseases, including bone marrow failure or leukemias. The success of HSC transplantation is however limited due to our inability to control HSC functions. The studies proposed in this application will provide important information of the physiologic role of p190-B RhoGAP in the regulation of HSC self renewal. Therefore, our study will guide designing strategies to modulate HSC functions via inhibition of p190-B Rho GAP that could be used in the future to device new therapeutic approaches of clinical HSC transplantation protocols.